Effectiveness of netakimab in psoriasis and psoriatic arthritis with concomitant metabolic syndrome

Read full text Summarise with VIRAT
Authors: L. A. Novikova, Elena V. Dontsova, Андрей Алексеевич Бахметьев, Лариса Николаевна Борзунова, A. Yu. Kuranosov, Наталья Александровна Воронькова
Cited by: 0
References: 28

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Psoriasis and psoriatic arthritis are characterized by a high prevalence, a chronic progressive course, the frequent presence of severe forms, comorbidities, and a significant decrease in patients’ quality of life, which justifies high demands on the efficacy and safety of therapy for these diseases. The article describes two clinical cases of the successful use of the interleukin 17 (IL-17) inhibitor netakimab in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. Netakimab was administered at a dose of 120 mg as subcutaneous injections once weekly on weeks 0, 1, and 2, followed by 120 mg once every 4 weeks. The treatment efficacy was assessed by clinical and laboratory examination using PASI, DAS28, and NAPSI scores. Netakimab treatment resulted in regression of subjective and objective skin symptoms and sustained clinical and laboratory remission of joint syndrome. Netakimab treatment was free of adverse events and significantly improved patients’ quality of life.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Dermatology and Skin Diseases

Publication details

Journal / source
Vestnik dermatologii i venerologii
Volume
102
Issue
1
Pages
68–75
Publication date
28 March 2026
Language
EN